版本:
中国

BRIEF-Lilly says phase 3 breast cancer study meets primary endpoint

March 20 Eli Lilly And Co

* Lilly announces phase 3 monarch 2 breast cancer study of abemaciclib met primary endpoint of progression-free survival

* Eli Lilly And Co - its monarch 2 trial of abemaciclib met primary endpoint of progression-free survival (pfs)

* Eli Lilly And Co- intends to submit a new drug application (nda) for single-agent abemaciclib in q2 of 2017

* Plans to submit an additional application for monarch 2 in q3 of this year Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐